<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605097</url>
  </required_header>
  <id_info>
    <org_study_id>H12-00557</org_study_id>
    <nct_id>NCT01605097</nct_id>
  </id_info>
  <brief_title>High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule</brief_title>
  <acronym>Dosepainting</acronym>
  <official_title>High Dose Rate Prostate (HDR) Brachytherapy Dose Escalation to Dominant Intra-prostatic Nodule for Patients With Intermediate and High Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the feasibility of using technology of ultrasound guided HDR&#xD;
      brachytherapy to focally increase dose to regions within the prostate that are heavily&#xD;
      infiltrated with cancer. Such regions, referred to as dominant intraprostatic lesions (DIL)&#xD;
      can be visualized using diffusion contrast enhanced MRI employing an endo-rectal coil. The&#xD;
      magnetic resonance (MR) images can be fused with the planning transrectal ultrasound (TRUS)&#xD;
      prior to the brachytherapy procedure to design a dose distribution that will encompass the&#xD;
      malignant volume with higher than the prescription dose. By its nature, brachytherapy has&#xD;
      subvolumes that receive (for example)125% of the prescription dose or 150% of the&#xD;
      prescription dose. With TRUS-guided and TRUS-planned HDR these areas can be manipulated to&#xD;
      coincide with the DIL. The limit of dose escalation has been reached at whole prostate&#xD;
      external beam doses of 81-86 Gy and still failure rates for intermediate and high risk&#xD;
      disease are unacceptable. There is much interest in focal dose escalation and TRUS-guided HDR&#xD;
      brachytherapy is perfectly suited to achieving this.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: If a dominant nodule is visualized on dynamic contrast enhanced (DCE) MRI, it will&#xD;
      be contoured in 3D and the images fused to the planning TRUS study that is done in&#xD;
      preparation for brachytherapy (of any type: seeds or HDR). The patient's treatment will&#xD;
      consist of the standard combined external beam (4600 centiGray (cGy) in 23 fractions) and HDR&#xD;
      brachytherapy boost (2 fractions of 1000 cGy given on days 5 and 15 of the external beam&#xD;
      course). During each HDR treatment the plan will be manipulated such that the normally&#xD;
      occurring high dose regions (125%, 150%) are positioned at the site of the identified&#xD;
      disease. Normally approximately 60% of the prostate volume receives 125% of the dose and 30%&#xD;
      receives 150%. By ensuring that the inherent dosimetry favors treatment of the known cancer,&#xD;
      no region of the prostate would be &quot;underdosed&quot;. HDR treatments are performed under general&#xD;
      anesthesia as an out patient procedure.&#xD;
&#xD;
      Statistical Analysis: This is a feasibility study and the data reported will be descriptive&#xD;
      including the frequency with which the DIL can be visualized in this population, the DIL&#xD;
      volume compared to total prostate volume, and the isodose that can encompass the DIL without&#xD;
      violating dose constraints to adjacent organs (urethra and bladder). Toxicity will be&#xD;
      monitored and efficacy will be assessed by repeat DCE MRI at 12 months and biopsy at 30&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Mean Dose to 90% of DIL Volume</measure>
    <time_frame>12 months</time_frame>
    <description>Feasibility of dose escalation to a minimum dose of 125% of prescription to 90% of the dominant intra-porstatic lesion (DIL) volume as defined on multiparametric endo-rectal magnetic resonance imaging (mpMRI) without exceeding critical organ dose constraints (Urethral volume receiving 115%= 0, Dose to 1cc of rectal wall &lt; 7 Gy). 2 Fractions were performed and the mean dose to 90% of DIL volume was averaged.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>24 months</time_frame>
    <description>Time to normalize International Prostate Symptom Score (months). Score range 0-35 with 35 being worst outcome. Normalization refers to a return to baseline urinary function prior to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen(PSA) Response at 5-years</measure>
    <time_frame>5 years</time_frame>
    <description>Efficacy assessed by biochemical PSA response reported at median 5 year follow up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>HDR interstitial brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR interstitial brachytherapy</intervention_name>
    <description>2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy</description>
    <arm_group_label>HDR interstitial brachytherapy</arm_group_label>
    <other_name>Planning soft ware Varian Medical Systems Vitesse III</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically proven adenocarcinoma of the prostate&#xD;
&#xD;
          -  intermediate or high risk prostate cancer&#xD;
&#xD;
               -  Intermediate risk prostate cancer patients must have:&#xD;
&#xD;
                    -  Clinical stage ≤ T2c,&#xD;
&#xD;
                    -  Gleason score = 7 and initial prostate specific antigen (iPSA) ≤ 20, or&#xD;
&#xD;
                    -  Gleason score ≤ 6 and iPSA &gt; 10 and ≤ 20.&#xD;
&#xD;
               -  High risk patients may have&#xD;
&#xD;
                    -  Clinical stage T3&#xD;
&#xD;
                    -  Gleason score 8-10&#xD;
&#xD;
                    -  PSA &gt; 20 ng/ml&#xD;
&#xD;
          -  fit for general anesthetic.&#xD;
&#xD;
          -  unilateral disease with either a palpable nodule or a cluster of positive biopsies&#xD;
             from a single region suggesting the presence of dominant nodule.&#xD;
&#xD;
          -  estimated life expectancy of at least 10 years.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.&#xD;
&#xD;
          -  no contraindications to interstitial prostate brachytherapy.&#xD;
&#xD;
          -  if on coumadin therapy must be able to stop safely for 7 days.&#xD;
&#xD;
          -  must not have any contraindications to MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does not meet staging criteria for intermediate or high risk prostate cancer&#xD;
&#xD;
          -  Does not have a localized high volume of intraprostatic disease&#xD;
&#xD;
          -  unfit for general anesthetic&#xD;
&#xD;
          -  MRI contraindicated&#xD;
&#xD;
          -  unable to stop blood thinners&#xD;
&#xD;
          -  Life expectancy &lt; 10 years&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Schmid, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Physicst</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Groenendaal G, van den Berg CA, Korporaal JG, Philippens ME, Luijten PR, van Vulpen M, van der Heide UA. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol. 2010 May;95(2):185-90. doi: 10.1016/j.radonc.2010.02.014. Epub 2010 Mar 16.</citation>
    <PMID>20231041</PMID>
  </reference>
  <reference>
    <citation>Kim Y, Hsu IC, Lessard E, Kurhanewicz J, Noworolski SM, Pouliot J. Class solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI. Radiother Oncol. 2008 Jul;88(1):148-55. Epub 2008 Feb 20.</citation>
    <PMID>18083260</PMID>
  </reference>
  <reference>
    <citation>Pouliot J, Kim Y, Lessard E, Hsu IC, Vigneron DB, Kurhanewicz J. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1196-207.</citation>
    <PMID>15234056</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <results_first_submitted>January 24, 2020</results_first_submitted>
  <results_first_submitted_qc>June 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate neoplasms</keyword>
  <keyword>interstitial radiation</keyword>
  <keyword>High dose rate prostate brachytherapy</keyword>
  <keyword>dose escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Aim of protocol was to have 25 patients for whom dominant lesion identified on MRI and dose escalation feasible with HDR brachytherapy</recruitment_details>
      <pre_assignment_details>One patient consented but ineligible because did not have a visible lesion on the MRI of his prostate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose Rate (HDR) Interstitial Brachytherapy</title>
          <description>HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion&#xD;
HDR interstitial brachytherapy: 2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">One patient consented but was ineligible due to lack of lesion visible on mpMRI</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HDR Interstitial Brachytherapy</title>
          <description>HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion&#xD;
HDR interstitial brachytherapy: 2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="51" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline PSA ng/mL</title>
          <description>Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis.</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" lower_limit="3.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason score</title>
          <description>Gleason score is assigned by pathologist on examination of prostate biopsy material and ranges from 2 to 10 with higher score representing more aggressive undifferentiated tumors</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gleason 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason 8 or 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>clinical stage</title>
          <description>Clinical Tumor Stage is assigned from combination of digital rectal exam and imaging. T1 representants tumor that is neither palpable nor visible on imaging. cT2a and cT2b represent palpable/visible disease that is either less than half of one lobe (cT2a) or more than half of one lobe(cT2b).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage T1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage T2a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage T2b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Mean Dose to 90% of DIL Volume</title>
        <description>Feasibility of dose escalation to a minimum dose of 125% of prescription to 90% of the dominant intra-porstatic lesion (DIL) volume as defined on multiparametric endo-rectal magnetic resonance imaging (mpMRI) without exceeding critical organ dose constraints (Urethral volume receiving 115%= 0, Dose to 1cc of rectal wall &lt; 7 Gy). 2 Fractions were performed and the mean dose to 90% of DIL volume was averaged.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Rate (HDR) Interstitial Brachytherapy</title>
            <description>HDR prostate brachytherapy with dose escalation to 1250 centiGray (cGy) to the MRI-defined dominant intraprostatic lesion&#xD;
HDR interstitial brachytherapy: 2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy</description>
          </group>
        </group_list>
        <measure>
          <title>Average Mean Dose to 90% of DIL Volume</title>
          <description>Feasibility of dose escalation to a minimum dose of 125% of prescription to 90% of the dominant intra-porstatic lesion (DIL) volume as defined on multiparametric endo-rectal magnetic resonance imaging (mpMRI) without exceeding critical organ dose constraints (Urethral volume receiving 115%= 0, Dose to 1cc of rectal wall &lt; 7 Gy). 2 Fractions were performed and the mean dose to 90% of DIL volume was averaged.</description>
          <units>Grays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.25" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Toxicity</title>
        <description>Time to normalize International Prostate Symptom Score (months). Score range 0-35 with 35 being worst outcome. Normalization refers to a return to baseline urinary function prior to treatment.</description>
        <time_frame>24 months</time_frame>
        <population>Months to normalization of International Prostate Symptom Score following treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>HDR Interstitial Brachytherapy</title>
            <description>HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion&#xD;
HDR interstitial brachytherapy: 2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Toxicity</title>
          <description>Time to normalize International Prostate Symptom Score (months). Score range 0-35 with 35 being worst outcome. Normalization refers to a return to baseline urinary function prior to treatment.</description>
          <population>Months to normalization of International Prostate Symptom Score following treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.6" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Specific Antigen(PSA) Response at 5-years</title>
        <description>Efficacy assessed by biochemical PSA response reported at median 5 year follow up.</description>
        <time_frame>5 years</time_frame>
        <population>All 25 underwent dose escalation to dominant lesion in prostate to median 132% of prescription dose</population>
        <group_list>
          <group group_id="O1">
            <title>HDR Interstitial Brachytherapy</title>
            <description>HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion&#xD;
HDR interstitial brachytherapy: 2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Antigen(PSA) Response at 5-years</title>
          <description>Efficacy assessed by biochemical PSA response reported at median 5 year follow up.</description>
          <population>All 25 underwent dose escalation to dominant lesion in prostate to median 132% of prescription dose</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.02" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collected for 60 months on all patients. Accrual was completed July 2013 and data collected to July 2018.</time_frame>
      <desc>CTCAE V 3.0</desc>
      <group_list>
        <group group_id="E1">
          <title>HDR Interstitial Brachytherapy</title>
          <description>HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion&#xD;
HDR interstitial brachytherapy: 2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>grade 1 proctitis</sub_title>
                <description>rectal discomfort, no intervention required</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>late hematuria grade 1</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Juanita Crook</name_or_title>
      <organization>BC Cancer</organization>
      <phone>250 712 3958</phone>
      <email>jcrook@bccancer.bc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

